Granules wraps up acquisition of Swiss CDMO Senn Chemicals for Rs 192.5 crore

HYDERABAD: Granules India Limited on Thursday said it has completed the acquisition of 100% stake in Swiss contract development & manufacturing organization (CDMO) Senn Chemicals for a consideration of Rs 192.5 crore.

Granules’ wholly owned Indian subsidiary Granules Peptides Pvt Ltd has acquired a stake in the 60-year-old company that specializes in peptide development and manufacturing from the Senn family.

Following the acquisition, the Senn Chemicals brand and its operations in Dielsdorf, Switzerland, will operate under Granules’ ownership, Granules said.

The acquisition, which follows the signing of a definitive share purchase agreement in February 2025, marks Granules’ entry into the rapidly growing peptide therapeutics segment as well as the CDMO space.

The company said the acquisition will enable Granules to accelerate development and manufacturing of GLP-1 receptor agonists and other peptide-based APIs, addressing the growing demand in anti-diabetic, anti-obesity, and other next-generation therapeutic areas.

Granules and Senn have already initiated joint development activities in this space, with a broader peptide API pipeline planned, it added.

Senn Chemicals has a strong presence in liquid-phase peptide synthesis (LPPS) and solid-phase peptide synthesis (SPPS) and caters to innovators and brand owners across pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets.

Dr Krishna Prasad Chigurupati, chairman & managing director, Granules India, said the acquisition marks a pivotal step in Granules’ strategic evolution into a science- and innovation-led organization. "By entering the rapidly growing peptide therapeutics segment and building on Senn’s specialized CDMO capabilities, we are well-positioned to deliver high-quality, next-generation treatments,” Chigurupati said.


Stay informed with the latest business news, updates on bank holidays and public holidays.

Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!